Ceritinib and Ranolazine
Determining the interaction of Ceritinib and Ranolazine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes. In pharmacokinetic studies, plasma levels of ranolazine (1000 mg twice a day) were increased 3.2-fold by the potent CYP450 3A4 inhibitor, ketoconazole (200 mg twice a day), and 1.8- to 2.3-fold by the moderately potent inhibitor diltiazem (180 to 360 mg/day). Plasma levels of ranolazine (750 mg twice a day) were increased about 2-fold by the CYP450 3A4 and P-glycoprotein inhibitor, verapamil (120 mg three times a day). MANAGEMENT: Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.
Professional:CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes. In pharmacokinetic studies, plasma levels of ranolazine (1000 mg twice a day) were increased 3.2-fold by the potent CYP450 3A4 inhibitor, ketoconazole (200 mg twice a day), and 1.8- to 2.3-fold by the moderately potent inhibitor diltiazem (180 to 360 mg/day). Plasma levels of ranolazine (750 mg twice a day) were increased about 2-fold by the CYP450 3A4 and P-glycoprotein inhibitor, verapamil (120 mg three times a day).
MANAGEMENT: Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ceritinib-Ranolazine ER Tablets
- Ceritinib-Rapaflo
- Ceritinib-Rapamune
- Ceritinib-Rapamune (Sirolimus Oral Solution)
- Ceritinib-Rapamune (Sirolimus Tablets)
- Ceritinib-Rapamune Tablets
- Ranolazine-Cerovite Jr
- Ranolazine-Certolizumab
- Ranolazine-Certolizumab Pegol
- Ranolazine-Certolizumab Prefilled Syringes
- Ranolazine-Certolizumab Subcutaneous
- Ranolazine-Certolizumab Vials